• Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS
• Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes
• NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor
• Company recently completed initial shipment to UK licensee

While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech market with sugarBEAT(R) – a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed to help diabetes patients manage glucose levels. Diabetes is a significant concern in the United States, according to a report released by the Center for Disease Control (“CDC”) that provides statistics across ethnicities, ages, education levels, and regions (https://ibn.fm/Ch1HI). According to the report, 34.2 million Americans – roughly 10 percent – have diabetes, and approximately one in three have pre-diabetes. “CDC is working to reverse the epidemic by helping to identify people with pre-diabetes, prevent type 2 diabetes and diabetes complications, and improve the health of all people with diabetes,” reads the report. “Through the National DPP’s evidence-based, affordable lifestyle change program, adults with pre-diabetes learn to make healthy changes that can cut their risk of type 2 diabetes by as much as 58% (71% for those over 60 years).” Controlling insulin is an essential part of the lifestyle changes required to manage and prevent diabetes, according to the US National Institute of Health (“NIH”) (https://ibn.fm/z5jJe). Accordingly, the medtech industry has grown considerably to meet the demand for insulin-monitoring equipment such as insulin pumps and CGM devices. While most businesses faced severe business restraints in 2021, the diabetes tech space had an eventful year with highlights that included climbing user numbers, expansion of coverage for glucose monitoring devices by the Centers for Medicare & Medicaid Services (“CMS”), and bullish analyst projections that forecast increased adoption of diabetes tech devices in 2022 and beyond. NMRD is currently in the process of commercializing its sugarBEAT(R) non-invasive, flexible, and affordable CGM device. With actionable insights from real-time glucose monitoring, sugarBEAT(R) is designed to help diabetic and pre-diabetic people prevent, manage, and reverse diabetes symptoms. As part of its marketing strategy, NMRD recently completed an initial shipment of sugarBEAT(R) devices to MySugarWatch Limited, its UK licensee. MySugarWatch Limited intends to market sugarBEAT(R) via a subscription-based diabetes coaching and management service that targets over 4.9 million diabetics and 13.6 million people with an increased risk of contracting Type 2 diabetes in the UK (https://ibn.fm/OdNBO). “This initial shipment of sugarBEAT(R) CGM devices to our UK licensee allows the Company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” said Nemaura CEO, Dr. Faz Chowdhury. “Starting in the UK, patients with Type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence, and outcome.” Founded in 2011, NMRD initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved into the wearables space at the intersection of global diabetes, pre-diabetes, and weight loss device markets. With diabetes and obesity on the rise, NMRD is dedicated to addressing the growing need for flexible, affordable glucose monitoring solutions that help prevent, manage, and reverse diabetes and pre-diabetic conditions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Lexaria received independent review board approval for its HYPER-H21-4 human clinical study for hypertension treatment
• The stage is also set for other R&D programs for the 2022 calendar year, including HOR-A22-1, DEM-A22-1, RHEUM-A22-1 and DIAB-A22-1
• All of these 2022 R&D programs are fully funded, with Lexaria having raised approximately $15 million over the 2021 calendar year
• Lexaria believes that these programs will build significant value for its stakeholders and pursue policies for substantial improvements to human health

In late 2021, Lexaria Bioscience (NASDAQ: LEXX) announced several new and ongoing R&D programs for its patented DehydraTECH(TM) technology. While making the announcement, Chris Bunka, the Chief Executive Officer (“CEO”), noted that Lexaria would continue to see significant milestones in utilizing DehydraTECH-CBD, focusing on heart disease and hypertension. “Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking,” noted Mr. Bunka. “We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease, and diabetes,” he added (https://ibn.fm/0HA7M). It received independent review board approval in what marks a significant milestone for its 2022 R&D program. The approval comes in less than two months after Lexaria announced that it was readying the study protocols for its HYPER-H21-4 study, its fourth recent human clinical study, and its most ambitious one yet (https://ibn.fm/aurm0). The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with and without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively, in a move that is intended to build significant value for all its stakeholders while also pursuing policies for substantial improvements to human health. All the R&D for the 2022 calendar year is fully funded, having raised approximately $15 million in funding over the 2021 calendar year. Lexaria is confident that data from the studies will support the company’s plans to enter regulatory pathways, which, it anticipates, will result in the regulatory approval to use DehydraTECH-CBD for the treatment of hypertension and possibly other types of cardiovascular disease. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SRAX’s performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M – $48M.
• Company’s SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance.
• As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M – $48M, an increase of 46% – 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8). With solutions built to bring clarity and make the digital space more transparent, SRAX aims to deliver unbiased data and reveal analytics for companies to manage ROI from investor relations programs and corporate communication firms. The company’s growth remains closely linked to Sequire, its SaaS platform. Last year the platform grew both in subscribers and functionality, resulting in considerable revenue growth and customer renewals. This year Sequire has a number of significant releases that will continue to enhance the platform’s value. Sequire’s success is driven by its focus on delivering solutions that solve important pain points for public companies. To stay competitive in today’s environment, companies need to better communicate with their shareholders and the broader investment community. As a data analytics platform designed for public companies to track essential data, SRAX provides unique opportunities for investors and public companies to connect and communicate through its Sequire SaaS platform. Sequire provides users with data that help them understand market activity and develop insights to engage their investor base. With this platform, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. SRAX has also expanded its model to include additional value-added services from the investor relations space, such as their preeminent industry conferences. The company owns LD Micro, a respected conference provider targeted at small and micro-cap markets. “Our team did excellent work in 2021, meeting and exceeding our guidance. The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M,” added Miglino. SRAX has seen its financial performance go from strength to strength over the past year, with recently reported results revealing exceptional revenue growth. Its remarkable performance and growth trajectory appear to have contributed to the increased investors’ interest, with several hedge funds and other institutional players adding to their stakes in the company (https://ibn.fm/J6IAL). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Over 466 million people current suffer from disabling hearing loss with a further 1.1 billion people at risk of suffering hearing damage
• Elevated device cost, poor after-sales service, and a lack of access to proper healthcare have led to only 14% of the 48 million American with hearing loss to currently use hearing aid devices
• InnerScope Hearing Technologies has sought to address this issue with its affordable direct-to-consumer sales model
• InnerScope CEO, Matthew Moore presented at the Emerging Growth Conference on January 5th, updating shareholders and investors on the company’s latest operational highlights

As of March 2019, the World Health Organization (“WHO”) estimated that disabling hearing loss affected around 466 million people across the globe, out of whom 34 million were children. Moreover, the WHO forecast that up to 1.1 billion people between the ages of 12 to 35 years globally were subject to hearing loss risk, largely due to constant noise exposure (https://ibn.fm/ftcaw). InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has long sought to become a leader in the direct-to-consumer hearing aid market, with the goal in mind to provide affordable hearing to the tens of millions of Americans suffering from hearing loss today. Elevated device costs, problems associated with devices such as post-purchase services, battery problems, and maintenance issues, along with poor access to adequate healthcare, are all factors that have historically contributed towards restricting the growth of the global hearing aid market. In fact, a recent White House Fact Sheet revealed that the elevated cost of hearing aids had led to only 14% of the approximately 48 million Americans with hearing loss using them (https://ibn.fm/pEwQI). In addition, a heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Nonetheless, the global hearing aid market is estimated to display a strong underlying growth trend over the coming years, with a forecast 6.6% CAGR between 2021-2028. Through its dedicated online portal, www.iHeardirect.com, InnerScope has looked to provide consumers with affordable, Bluetooth app-controlled, self-adjusting hearing technology in a prompt and affordable manner. The company’s HearIQ App for iPhone and Android has been designed to include a free self-check hearing test, providing billions of people worldwide with the means to detect and self-diagnose early-onset hearing loss. Meanwhile, the company’s proprietary hearing technology provides customers with the ability to personalize each hearing device to their hearing needs in under 10 minutes. InnerScope Hearing Technologies recently acquired HearingAssist, a long-established leader in the direct-to-consumer hearing aid market and Walmart’s largest hearing aid supplier, for a gross consideration of $10 million, with the express intent to create a “powerful disruptive company in the global hearing device market.” At the time of acquisition, Matthew Moore, President and CEO of InnerScope, stated, “Today is a tremendous milestone for InnerScope. I’m delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market.” Separately, InnerScope Hearing has revealed that Matthew Moore was invited to present at the Emerging Growth Conference, a live interactive online event that took place on Wednesday 5^th January, which allowed InnerScope’s existing shareholders and the investment community to interact with InnerScope’s CEO in real-time. Interested investors. You can watch Moore presentation by clicking on the link: https://www.youtube.com/watch?v=QuAndXZLbMk Moore’s presentation highlighted InnerScope’s two recent direct-to-consumer hearing aid company acquisitions with iHear Medical Inc., its 40+ patents, and its iHearTest, the only FDA-cleared, in-home hearing test on the market and sold at CVS Pharmacy’s; and HearAssist II LLC., Walmart’s largest hearing aid supplier. In addition, Moore discussed InnerScope’s 2022 growth trajectory with these pivotal acquisitions and a key partnership with Atlazo Inc., a leader in intelligent semiconductor solutions, to develop new types of unprecedented artificial intelligence hearing products. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• President and CTO Dean Rositano was invited to be a new member of the prestigious Rolling Stone Culture Council – an invitation-only network of leaders who are on the cutting edge of culture, community, and the Rolling Stone brand
• Artist Republik will join Fan Pass Live as a Friendable Company, increasing the number of artists on the platform
• CEO and Co-Founder Robert Rositano Jr. explained that one of the company’s main goals has always been to test multiple entry points to gain exposure in the music industry for artists and fans alike

Mobile technology and marketing company Friendable (OTC: FDBL) has achieved several important milestones throughout 2021 and has big things planned for the new year as well, focusing mostly on further scaling its Fan Pass Live artist streaming platform offering and expanding its industry relationships. Taking one step closer to achieving the latter, the company announced that President and CTO Dean Rositano was invited to be a part of the prestigious Rolling Stone Culture Council (https://ibn.fm/lbXDe). The Council is an invitation-only network of leaders who are on the cutting edge of culture, community, and all it takes to be associated with the Rolling Stone brand. Mr. Rositano was invited to be a part of this community because of his contributions to the music, entertainment, and technological industries. This includes his successful development of automated solutions, services, and technology that enable artists to take true ownership and control over their music and careers. Mr. Rositano has the honor of joining senior leaders from across North America and Europe in music, art, technology, fashion, gaming, media, sports, and entertainment. “Mr. Dean Rositano is an inspiring leader, and we value the knowledge and experience he brings to this community,” Council Co-Founder Scott Gerber said. “The Council brings together members with the right mix of expertise, passion, and energy to do great things. Individuals, businesses, and industries all benefit from the learning and collaboration happening inside.” The announcement follows another major milestone that was recently announced by the company: the closing of the acquisition of Artist Republik, a reputable music distribution company (https://ibn.fm/4fIiX). Following the acquisition transaction completion, Artist Republik is now officially a Friendable Inc. company alongside Fan Pass Live. The new acquisition will add approximately 100,000 artists to the platform and triple the technology deck. The acquisition comes after approximately one year of talks and negotiations between the two companies to seal a partnership, as Artist Republik was moving toward the development of livestream services and Fan Pass was moving toward its own music distribution offering. According to CEO Robert Rositano Jr., Friendable was also able to retain the Artist Republik CEO and CTO as initial consultants after the acquisition, assisting with integration efforts and expanding the service offering. Artists will also receive more autonomy and freedom over their music, ticketed streams, blog/social promotions, exclusive merchandise development, sales, and more. All of this is available to artists without the requirement to give up their musical rights. Friendable also provided the public and its shareholders with a summary of milestones for 2021 and the plans made for 2022. The company has come a long way since its flagship offering, Fan Pass Live artist streaming platform, was released in July 2020, with 16 artists performing live on the platform at the time of the launch. In February 2021, the platform set a record for artist signups, reaching over 350% growth compared to the previous month, including 100% growth in livestream events. By July 2021, when an updated version with new features and options was released, the platform had surpassed 5,000 artist members. In a company press release detailing achievements and strategies, Rositano Jr. thanked all artists members, fans, partners, supporters, team, and shareholders (https://ibn.fm/ysLxn). “We would not be here without each and every one of you pulling for us, and the progress certainly shows we are on the correct path,” he said. Rositano Jr. also said new service offerings will be announced soon as the company expands into various channels of music distribution, working towards the same goal of scaling revenues, number of artists and fan subscribers on the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

MSLs are critical in ensuring that products are used efficiently throughout their lifecycle. They serve as scientific peers and resources within the medical community, and provide valuable expertise to internal colleagues. MSLs, like the rest of the life science industry, must quickly adapt to the introduction of new technological platforms and rethink their workload in the post-COVID era. DGE will cordially welcome many professionals to attend the 2nd annual Next-Gen MSL Excellence Symposium, the only industry event dedicated to conquering the daily problems that this critical group faces while achieving career milestones and adjusting to new technology! This symposium is the only virtual industry event dedicated to the work problems encountered by MSLs, emphasizing the relevance of their role in drug and device development as well as adjusting to new technologies in the post-COVID era. Why Should You Attend It?

• Strategies for outlining and achieving professional objectives
• A guide for developing the leadership qualities to advance in your career path
• Key methods for enhancing KOL engagements by honing communication and soft skills.
• Techniques for collaborating well with cross-functional teams and participating in strategic planning
• Innovative ways to use artificial intelligence and social media to gather information and impact medical policy
• Learning and networking with field medical professionals and industry leaders in an interactive online platform

DGE’s 2nd Next-Gen MSL Excellence Symposium will provide a dynamic platform for medical industry KOLs and decision-makers to share their perspectives and discuss the role of MSLs in the changing landscape. They will also provide valuable tips and techniques for building a successful career and demonstrating the value of their skills to the company. This conference is also a fantastic chance for talented individuals interested in pursuing a successful MSL career. Medical Affairs personnel will contact teams that conduct similar duties in order to gain new and expanded ideas and roles. For more information, visit https://ibn.fm/aHMOd.

• Hollywall owns the rights to and music recordings of more than 17,500 songs, in addition to the rights to 29 video games and a film
• As of December 2019, the company’s music library was valued at $146 million
• The music industry has witnessed an upsurge in music catalog acquisitions by investment and management firms and leading music companies
• Hollywall is led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments

The 2010s saw an upsurge in music catalog acquisitions, a trend that only accelerated into the 2020s. Describing this “catalog acquisition frenzy,” a January 2021 Rolling Stone Magazine article observed that even investment and management firms and Wall Street companies had entered into the music business by buying rights to famous musicians’ creative works (https://ibn.fm/UCEZK). “Right now, the gorillas in this jungle include Larry Mestel’s Primary Wave and Merck Mercuriadis’s Hipgnosis Songs Fund, two investment and management firms: in 2021 alone, the latter company acquired copyrights and/or income streams from Neil Young, Lindsey Buckingham of Fleetwood Mac, Shakira, and Jimmy Iovine,” reads the article. “This isn’t the first time in recent memory that Wall Street mammoths have gotten involved in the inner workings of the music business,” the article continues. “In 2016, BlackRock (a company with $7.8 trillion in assets under management) led a $300 million investment into Primary Wave – money that was subsequently spent on legendary music catalogs like Bob Marley’s.” Leading music companies such as Warner Music Group and Universal Music Group have also splurged tens of millions of dollars on music catalogs. The logic behind such acquisitions is simple. Firstly, master recordings earn revenue through various avenues, namely sampling, streaming and purchases/downloads, public broadcast, and use in television, film, and commercials. Secondly and according to a 2020 Variety Magazine article, “Publishing assets are currently running at multiples well over 12 with master rights slightly lower but increasing in value… In five to 10 years, it might be 20x – the value continues to rise” (https://ibn.fm/OBLpT). Notably, the market multiple analysis is a valuation approach that applies an EBITDA multiple or Net Publisher’s Share (“NPS”)/Net Label’s Share (“NLS”) multiple based on recent precedent acquisitions. It is used to derive a catalog’s implied market value (https://ibn.fm/Mjfe2). The increasing interest in music catalogs and their projected rise in value bodes well for Hollywall Entertainment (OTC: HWAL), an entertainment, media, infrastructure, telecommunication, technology, and broadcasting company that operates through various subsidiaries. The company, which serves some of the finest creators, writers, developers, and music artisans of our time by offering a business solution and distribution platform that maximizes a global audience reach, wholly owns an extensive music and entertainment library. Hollywall’s asset portfolio includes copyrights, legal rights, trademarks, and master recordings of over 17,500 songs, one of the largest master recording libraries globally. This library features hit songs from the likes of Michael Jackson, Elvis Presley, The Jacksons 5, Marvin Gaye, Dolly Parton, Frank Sinatra, The Who, Bob Marley, Quincy Jones, James Taylor, and more. In addition, HWAL owns the source code, rights, and trademarks of 29 video games and the rights to a film titled ‘The Elvis I Knew.’ With a fair value of about $146 million as of December 31, 2019, according to an intangible asset valuation prepared by Sun Business Valuation and available on the HWAL’s website (https://ibn.fm/3SdFe), Hollywall’s master recordings are only bound to increase in value as time progresses, positioning HWAL for growth well into the future. Led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments, Hollywall is favorably poised as one of the entertainment industry’s most exciting companies. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms
• The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation on psychedelics. Delic announced that the Company’s Co-founder and Chief Executive Officer, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference, held in an entirely virtual format from January 10-13, 2022. In addition to carrying out one-on-one meetings throughout the course of the conference, Mr. Stang made a corporate presentation on Delic Corp’s expansion strategy and overall industry outlook for the general public. H.C. Wainwright & Co., a full-service investment bank dedicated to providing investment banking, equity research, sales and trading, as well corporate access and strategic advisory services, celebrated 150 years of service in 2018. The firm has gained a well-deserved reputation for its innovative conference line-up over the years, having recently hosted events on topics as varied and diverse as psychedelics, mining, precision oncology, hepatitis B, ophthalmology, cryptocurrencies, blockchain technology and applications, and many more. The H.C. Wainwright Bioconnect Conference, hosted by former FDA commissioner Dr Scott Gottlieb, has sought to bring together a carefully curated collection of cutting-edge biopharmaceutical firms alongside institutional investors, private equity firms, venture capitalists, and industry executives. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/Bu2g4). With the sector on the cusp of broad-based legalization, the psychedelic wellness market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/jFEPL). Delic has sought to capitalize on the sector’s growth as well as rising demand for psychedelic products and services through the expansion of its proprietary Ketamine Wellness Centers (“KWC”), the largest chain of psychedelic wellness clinics in the country, with 15 more clinics opening in the next 18 months. Delic has also looked to expand its footprint within the sector through its other related businesses, which include Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the world’s largest psychedelic wellness event; as well as media platforms, Reality Sandwich and Delic Radio. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Company marked host of major milestones and accomplishments in 2021
• Approvals, licenses, expansions and growth all essential pieces of Cybin success
• CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022

As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. “2021 was an exciting year for Cybin,” said Cybin CEO Doug Drysdale. “We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months.” And that’s just the beginning for the emerging leader in the psychedelics industry. The company points to several key highlights this past year as proof positive it is on the right road to psychedelic success. Ranking at the top of 2021 milestones were the notice of allowance awarded from the U.S. Patent and Trademark Office for Cybin’s CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for the company’s cofunded investigator-initiated phase 2 clinical trial. Using the EMBARK psychedelic facilitator training program, the trial is designed to evaluate psychedelic-assisted psychotherapy to treat frontline clinicians experiencing COVID-related distress. In addition, company leaders confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding CYBN’s lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder. Cybin also announced positive CYB003 data showing significant advantages compared to oral psilocybin for the treatment of mental health disorders, including a 50% reduction in variability, a 50% reduction in dose, a 50% shorter time to onset and nearly double brain penetration. Other 2021 highlights for Cybin included receiving a grant for a psychedelic treatment clinic at Lenox Hill Hospital, part of the largest healthcare system in New York State, to benefit underserved communities; being granted a schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab, which will allow the company to expand its internal R&D capabilities; receiving approval from the FDA for its investigational new drug application to proceed with a company-sponsored feasibility study using the Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics; and the completion of 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. There were many more 2021 highlights for Cybin, which expanded operations into Europe and was the first psychedelic company to list on the NYSE American market. “Driven by promising and differentiating preclinical data, our innovative operational and R&D pipeline platforms expect to support four first-in-human clinical studies in 2022, which we hope will progress our proprietary psychedelic development candidates CYB003 and CYB004 closer toward potential approval for treating depression and addiction disorders,” Drysdale stated. “We believe 2022 will be a truly transformative year for Cybin.” Cybin is a leading ethical biopharmaceutical company on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development
• He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year
• Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market
• Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap digital health platform

Josh Bartch, the Co-Founder, Chairman, and Chief Executive Officer (“CEO”) of Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), recently appeared on The Bell2BellPodcast, a platform meant to highlight key organizations, leaders and entrepreneurs who are leaving a mark in their respective industries. Mr. Bartch briefly shared his background, leading up to co-founding Mydecine, along with the goals for the company for the new year. Of note was Mydecine’s phased approach, which Bartch noted is integral to the company’s operations, along with its future. “Mydecine Innovations Group…is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a blueprint or starting point and then making several improvements for what we call second-generation psychedelic molecules for the treatment of a number of indications,” Bartch noted (https://ibn.fm/kLsnW). So far, Mydecine addresses two lead indications- smoking cessation and PTSD. In 2021, the company partnered with Johns Hopkins University (“JHU”) for further research on smoking cessation and has so far made some significant strides in PTSD treatment. In addition, its phased approach, which entails understanding the imperfections of initial formulations and then modifying them to make them more effective, has already set the company apart from its peers. As a result, the first generation of products is already proving significantly better than what is currently available in the market. “For smoking cessation, for instance, you’re looking at no good solutions currently available,” noted Mr. Bartch. “You have Chantix, which was recently recalled for a cancer-causing carcinogen…Even before, when it was still available on the shelf, this is a blockbuster drug doing $1.2 billion per year with efficacy data in the single digits at 12 months,” he added. With what Mydecine is offering, Bartch noted, early-stage trials have proven to be way better than what was available in the market. Efficacy data has shown upwards of 80% in six months and 67% at 12 months, all attributed to its phased approach. “Through our phased approach, we take that first generation, look at imperfections and make improvements- things in the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc.,” Bartch reckoned. Going into 2022, Mr. Bartch was keen to note that Mydecine will start two clinical trials- a smoking cessation study and a PTSD Phase 2a study. He also noted the company’s commitment to focusing more on novel compound production and getting them to clinics around the country, which will also be accompanied by publishing pre-clinical results following the studies carried out so far. 2022 will also be the year when Mydecine commercializes its Mindleap digital health platform, as it focuses on growing the number of its users and further improving its offering. To listen to the whole podcast, please visit https://ibn.fm/JQwe2 For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF